Pharmacokinetic Data Show That Oxolinic Acid and Flumequine Are Absorbed and Excreted Rapidly From Plasma and Tissues of Lumpfish by Haugland, Gyri Teien et al.
ORIGINAL RESEARCH
published: 12 November 2019
doi: 10.3389/fvets.2019.00394
Frontiers in Veterinary Science | www.frontiersin.org 1 November 2019 | Volume 6 | Article 394
Edited by:
Nora Mestorino,












This article was submitted to
Veterinary Pharmacology and
Toxicology,
a section of the journal
Frontiers in Veterinary Science
Received: 29 August 2019
Accepted: 24 October 2019
Published: 12 November 2019
Citation:
Haugland GT, Kverme KO,
Hannisdal R, Kallekleiv M,
Colquhoun DJ, Lunestad BT,
Wergeland HI and Samuelsen OB
(2019) Pharmacokinetic Data Show
That Oxolinic Acid and Flumequine
Are Absorbed and Excreted Rapidly
From Plasma and Tissues of
Lumpfish. Front. Vet. Sci. 6:394.
doi: 10.3389/fvets.2019.00394
Pharmacokinetic Data Show That
Oxolinic Acid and Flumequine Are
Absorbed and Excreted Rapidly From
Plasma and Tissues of Lumpfish
Gyri T. Haugland 1*, Karen O. Kverme 1, Rita Hannisdal 2, Marielle Kallekleiv 1,
Duncan J. Colquhoun 3, Bjørn Tore Lunestad 2, Heidrun I. Wergeland 1 and
Ole B. Samuelsen 2
1Department of Biological Sciences, University of Bergen, Bergen, Norway, 2 Fish Health Research Group, Institute of Marine
Research, Bergen, Norway, 3 Fish Disease Group, Norwegian Veterinary Institute, Oslo, Norway
This study examined the uptake, tissue distribution and elimination of the antibacterial
agents oxolinic acid and flumequine in lumpfish (Cyclopterus lumpus L.) by use of
LC-MS/MS following a single oral administration of 25 mg/kg fish given in feed. Lumpfish
are increasingly used as cleaner fish for removal of sea lice on commercially farmed
salmon. The production of lumpfish is successful, but there are challenges with bacterial
infections and the number of antibacterial treatments has increased in recent years. As
the lumpfish is a novel species to farming, there is a need for pharmacokinetic data
and establishment of protocols for efficient antibacterial treatment. The current study
describes the pharmacokinetic properties of oxolinic acid and flumequine in lumpfish.
Absorption of oxolinic acid was moderate and was characterized by a calculated peak
plasma concentration (Cmax) of 2.12µg/ml after 10.3 h (Tmax) and an elimination half-life
(t1/2β) of 21 h. Area under curve (AUC) and AUC from 0 to 24 h (AUC0−24h) were
calculated to be 60.9 and 34.0 h µg/ml, respectively. For flumequine, plasma Cmax was
found to be 2.77µg/ml after 7.7 h (Tmax) with t1/2β of 22 h. The area under the curve
(AUC) and AUC from 0 to 24 h (AUC0−24) were calculated as 104.3 and 50.3 h µg/ml,
respectively. Corresponding Cmax values in muscle, liver, and head-kidney for oxolinic
acid were 4.01, 3.04, and, 4.68µg/g, respectively and Tmax of 11.1, 9.2, and 10.0 h,
respectively. For flumequine, Cmax values of 4.16, 4.01, and 7.48µg/g were obtained
in muscle, liver, and head kidney, respectively, with corresponding Tmax values of 10.2,
10.3, and 6.0 h. Antimicrobial susceptibility values as determined by minimum inhibitory
concentration (MIC) analyses against 28 isolates of Aeromonas salmonicida isolated from
diseased lumpfish ranged from 0.06 to 15µg/ml for oxolinic acid and 0.024 to 6.25µg/ml
for flumequine. Bimodal distributions in susceptibility to both oxolinic acid and flumequine
were observed. The combination of pharmacokinetic properties and MIC data make
possible calculation of efficient treatment doses, which are needed to improve the welfare
of lumpfish and minimize development of antibiotic resistant bacteria.
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INTRODUCTION
In recent years, lumpfish (Cyclopterus lumpus L.) and different
species of wrasse are deployed in salmon farms as cleaner fish
to removed lice from Atlantic salmon (1–3). While most of the
wrasses are wild caught, the supply of lumpfish is based strictly on
farmed individuals and the demand has led to an increase in the
production of lumpfish in Norway, from around 0.4 million in
2012 to 30 million in 2018 (http://www.fiskeridir.no). However,
like other fishes, lumpfish are susceptible to bacterial infections
including those caused by atypical Aeromonas salmonicida,
Pasteurella sp., Pseudomonas anguilliseptica, Vibrio anguillarum,
and Vibrio ordalii (4–7). All lumpfish are vaccinated, but
while currently available commercially vaccines show promising
results, lumpfish are vulnerable to infections prior to vaccination
and immediately post-vaccination, before vaccines can award
protection (8, 9). Pasteurella sp. and P. anguilliseptica are not yet
included in the vaccines. Over the last 7 years, the frequency of
identification of pathogenic bacteria in lumpfish has increased
significantly, from 12 cases in 2012 to 61 cases in 2018 (5). To
treat a bacterial infection, the use of antibacterial agents can be
appropriate. In Norwegian salmon farming, the consumption of
antibacterial agents has been low for the last 25 years reflecting
the low impact of bacterial infections in this species (statistics
provided by www.fhi.no). Still, there has been an increase in
the number of registered prescriptions in recent years due to
treatment of lumpfish. However, as lumpfish are generally very
small at the time of treatment this contributes little to the total
volume of antibacterial agents used (10).
Today, the two antibacterial agents commercially available
as medicated feeds in Norway are oxolinic acid (OA) and
florfenicol (FFC). FFC is a thiamphenicol derivative, while OA
and flumequine (FLU) belong to the group of antibacterial agents
called quinolones. Quinolones can be effectively administered
orally in fish via medicated feed and possess excellent
antibacterial activity against common bacterial infections caused
by A. salmonicida subsp. salmonicida (furunculosis), atypical
A. salmonicida (atypical furunculosis), V. anguillarum (classical
vibriosis), Vibrio salmonicida (cold-water vibriosis), and Yersinia
ruckeri (yersiniosis). Therefore, quinolones have been widely
used to treat systemic bacterial infections in fish (11–18). The
pharmacokinetics of OA and FLU have been studied in cold
water species like Atlantic salmon, Atlantic cod (Gadus morhus
L.) and Atlantic halibut (Hippoglossus hippoglossus L.) (19–
24). These studies show that species dependant differences in
pharmacokinetic parameters are common for both FLU and OA.
Bioavailability values of 65 and 31%, and plasma elimination
half-lives (t1/2 β) of 74 and 43 h have been reported for FLU
in Atlantic cod and Atlantic halibut, respectively (20, 25).
For OA, major differences in bioavailability were identified
in Atlantic cod and Atlantic halibut with values of 55 and
15% reported, respectively (21, 24). The largest difference in
elimination rate (t1/2β) for OA was between Atlantic cod and
Atlantic salmon with 84 and 15 h, respectively. These differences
clearly show that the pharmacokinetic properties of a drug
should always be investigated in the species in which it is
intended to be used.
A practical application of pharmacokinetic data is the
design of treatment regimens and prediction of possible clinical
outcomes. To establish a correct dosage regime and promote
optimal use of an antibacterial agent, both the pharmacokinetic
properties of the drug and the susceptibility of the pathogen to
the compound are required.
The aim of this study was to examine the pharmacokinetic
properties of the quinolones OA and FLU in lumpfish following
oral administration, and to relate these data to the minimum
inhibitory concentration (MIC) values for A. salmonicida strains
isolated from diseased lumpfish.
MATERIALS AND METHODS
Experimental Fish
Unvaccinated lumpfish (C. lumpus L.) were obtained from
Fjord Forsk AS (Sogndal, Norway), transported to the Aquatic
and Industrial Laboratory (ILAB), Bergen, Norway, and kept
in flow-through storage tanks (500 l) until the fish reach a
mean weight of 113.5 ± 25.0 g and a length of 11.7 ± 1 cm.
The seawater had a salinity of 34‰, a temperature of 12.0 ±
0.5◦C and a flow-rate of ∼1,000 l/h. The fish were fed a non-
medicated ration of 1% body weight per day of dry pellets (Amber
Neptun, 1.5mm pellets; Skretting, Norway) and were starved
for 2 d prior to- and 24 h post- antimicrobial administration.
The experiment was approved by the Norwegian Food Safety
Authority (ID 10178).
Administration of Feed
Commercially available OA medicated feed (5 g kg−1, Skretting)
was utilized. FLU medicated feed (5 g kg−1) was made by
coating 1.5mm Amber Neptun pellets (Skretting, Norway) with
a premix of (1:1 w/w) glucose:FLU (Sigma). The final in-feed
concentration of FLU was determined to be 5.2 ± 0.8 g per kg
using LC-MS/MS as described below. The pellets were mixed 1:1
with milliQ water and homogenized as described previously (26)
to make a paste, which was easily administered to the fish via a
silicone hose and a syringe. The amount of feed administered to
each fish corresponded to a dose of 25mg OA or 25mg FLU per
kg fish, which is the dose recommended from the feed producer.
Permission to make medicated feed with FLU was obtained from
The Norwegian Medicines Agency.
Sampling
To ensure as accurate sampling as possible for the first four
samplings, four groups of six fish were placed in individual
tanks (15 l, with through flow) following p.o. administration. The
remaining fish were kept in a 500 l tank. Samples were taken
at 3, 6, 12, 24, 48, 96, 144, 192, and 240 h post-administration
for OA, and at 3, 6, 12, 24, 48, 72, 96, 120, and 168 h post-
administration for FLU. At every sampling point, six fish were
killed by a blow to the head and samples of plasma, muscle,
head kidney and liver tissues were obtained. Blood (0.2–0.5ml)
was sampled from the caudal vein using a 1ml syringe. Plasma
was isolated by centrifugation of blood at ∼2,000 g for 10min.
All samples were immediately frozen and stored at −20◦C
until analyzed.
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Analyses of FLU and OA
For the analysis of FLU an internal standard (FLU-13C3;
Sigma Aldrich) was added to the homogenized tissue samples
and plasma (0.1ml). The analytes were extracted using 0.5%
formic acid in acetonitrile. The samples were vortex-mixed and
centrifuged before the extracts were transferred to a new vial
and concentrated at 40◦C under nitrogen flow. The residues
were dissolved in water/methanol (60:40) and filtered through
a 0.45µm filter. Analysis was performed using an Agilent 1290
LC-system (Agilent Technologies) coupled to an Agilent 6460
triple quadrupole mass spectrometer (Agilent Technologies). The
instrument was equipped with an electrospray ionization ESI
source operated in positive mode. The analytes were separated
by a reverse phase Agilent stable bond C18-column (150 ×
2.1mm i.d., 1.8µm particle size) (Agilent Technologies) using a
0.4 ml/min flow. The mobile phase was a mixture of methanol
and 0.1% formic acid in water. Chromatography was performed
utilizing a stepwise gradient: 0–0.3min, 20% methanol; 1.5min,
80% methanol; 2.1–2.1min, 95% methanol; 2.2–4.0min, 20%
methanol. All gradient steps were linear. The retention time for
FLU and FLU-13C3 was 2.0min. The following source conditions
were used: gas temperature: 200◦C; gas flow: 6 l/min; nebulizer
pressure: 35 psi; sheath gas temperature: 350◦C; sheath gas flow:
12 l/min; capillary voltage: 4,000V; nozzle voltage: 0 V. The
analytes were monitored using the following transitions: 262.9
m/z→ 245.0 m/z (quantifier) and 262.9 m/z→ 203.0 m/z
(qualifier); FLU-13C3, 265.9 m/z→ 248.0 m/z. Procedural blank,
matrix blank, matrix-matched calibration curve and controls
were prepared for each series. The limit of quantification (LOQ)
for FLU was determined as 10 ng/g in tissues, and 10 ng/ml in
plasma. The method was linear over the range studied (LOQ-
−25,000 ng/g). Recovery ranged from 90 to 110%, and relative
standard deviation was <10%.
The analysis of OA was performed in a similar manner as
described for FLU. However, OA-d5 (Sigma Aldrich) was used
as internal standard and acetonitrile was used for extraction.
The retention time for OA and OA-d5 was 1.8min. OA and the
internal standard weremonitored using the following transitions:
OA, 262.9 m/z→ 245.0 m/z (quantifier) and 262.9 m/z→ 217.0
m/z (qualifier); OA-d5, 267.9 m/z→ 250.0 m/z. Procedural
blank, matrix blank, matrix-matched calibration curve and
controls were prepared for each series. The LOQ for OA was
determined to 2.0 ng/g in tissue and 2.0 ng/ml in plasma. OA was
linear up to 15 000 ng/g. Recovery ranged from 90 to 110%, and
relative standard deviation was <10%.
Pharmacokinetic Analysis
Standard pharmacokinetic parameters were calculated using
the computer program PCNONLIN version 4.2 (Statistical
Consultants Inc., Lexington, KY, USA) using the best-fit
relationship between mean plasma or tissue drug concentrations
and time. Best-fit models were chosen using Akaike’s information
criterion estimation in which all data were weighted to produce
the best-fit curve (27). Elimination half-life (t1/2β) was calculated
using logarithmically (ln) transformed drug concentrations in the
elimination phase vs. time using the formula t1/2 = ln2/k, where
k is the slope of the regression line.
Bacterial Culture
Twenty-eight isolates of A. salmonicida isolated from diseased
lumpfish from different locations in Norway were cultured in
tryptic soy broth (TSB) at 20◦C, 200 rpm until late log phase.
The number of cells were determined using the cell counter
CASY Modell TT 150µm (Roche Diagnostics) and diluted to a
concentration of 5× 106 bacteria ml−1.
Minimum Inhibitory Concentration (MIC)
Determinations
The MICs were performed using microtiter plate with 96-well
with rounded bottom (Sarstedt AG & Co.). A 2-fold dilution of
OA and FLU (Sigma) suspended in TSB in the range of 0.00002–
60µg/ml and 0.0008–400µg/ml, respectively, were performed.
Three parallels were performed for each concentration. One
hundred microliters of bacterial suspension (5 x 106 bacteria/
ml) were mixed with 100 µl of antibacterial agent diluted in
TSB. Negative controls containing bacterial suspension, but no
antibacterial agents were included for each isolate. The plates
were sealed with microseal “B” PCR Plate sealing film (BIORAD)
and incubated at 20◦C for 48 h. The MICs were determined after
visual inspections, and given as the concentrations where no
growth was observed.
Statistical Analyses
Analysis of variance (ANOVA) was performed using the
statistical software package SigmaStat 3.5 to evaluate the effect
of time. If the variance was not normally distributed, the P-value
cut off was set to 0.01 as suggested by Glass et al. (28). The Holm-
Sidak method was performed for pairwise multiple comparison.
RESULTS
The mean concentrations of OA and FLU in plasma, muscle,
liver, and head-kidney obtained from a single oral administration
to six fish at each sampling point are shown in Tables 1, 2,
respectively. For plasma and all tissues, the highest level of OA
was measured 12 h post-administration (Figure 1). The highest
concentration at 12 h post-administration was in head kidney,
followed by muscle, liver, and plasma. Statistically significant
differences are shown in the Figure 1 as single letters. Plasma
data were used to calculate the pharmacokinetic parameters
using PCNONLIN. Plasma data for OA was best described by
an open one-compartment model with first-order input, first-
order output and a lag-time. The peak plasma concentration
(Cmax) was calculated to be 2.12µg/ml, the time to peak plasma
concentration (Tmax) to be 10.3 h and the absorption (t½α) and
elimination halflife (t½β) to be 6 and 21 h, respectively. Area
under the curve (AUC) and AUC from 0 to 24 h (AUC0−24h) were
calculated to be 60.9 and 34.0 h µg/ml, respectively.
For FLU, the highest concentration in plasma, head kidney
and liver wasmeasured 6 h post-administration, while formuscle,
the highest concentration of FLU was 12 h post-administration.
Statistical significant differences are shown in Figure 2 as single
letters. Plasma data for FLU were best described by an open one-
compartmentmodel with first-order input, first-order output and
no lag-time. Plasma Cmax, Tmax, t½α, t½β, AUC, and AUC0−24h
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TABLE 1 | Mean concentration of oxolinic acid (OA) in plasma (µg/ml) and tissue (µg/g) at different time points post oral administration of 25 mg/kg.
Sample Time (h)
0 3 6 12 24 48 96 144 192 240
Plasma LOQ 0.49 ± 0.17 1.47 ± 0.75 2.23 ± 1.01 0.87 ± 0.40 0.25 ± 0.06 LOQ LOQ LOQ LOQ
Head kidney LOQ 2.05 ± 1.92 3.32 ± 1.18 5.26 ± 2.39 1.97 ± 0.75 0.49 ± 0.15 LOQ LOQ LOQ LOQ
Liver LOQ 1.52 ± 0.73 2.67 ± 1.14 2.91 ± 1.28 1.27 ± 0.39 0.43 ± 0.10 0.02 ± 0.01 LOQ LOQ LOQ
Muscle LOQ 0.90 ± 0.52 2.75 ± 1.31 4.25 ± 1.95 2.12 ± 1.22 0.42 ± 0.13 0 LOQ LOQ LOQ
TABLE 2 | Mean concentration of flumequine (FLU) in plasma (µg/ml) and tissue (µg/g) at different time points post oral administration of 25 mg/kg.
Sample Time (h)
0 3 6 12 24 48 72 96 120 168
Plasma LOQ 1.91 ± 0.59 2.93 ± 0.87 2.50 ± 0.47 1.49 ± 0.65 0.34 ± 0.12 0.09 ± 0.13 LOQ 0.02 ± 0.04 LOQ
Head kidney LOQ 6.23 ± 5.47 7.48 ± 3.20 4.88 ± 1.03 3.25 ± 1.89 0.45 ± 0.26 0.08 ± 0.12 LOQ 0.01 ± 0.02 LOQ
Liver LOQ 4.14 ± 1.69 6.08 ± 2.79 4.69 ± 0.82 2.48 ± 1.03 0.66 ± 0.25 0.18 ± 0.25 0.03 ± 0.01 0.02 ± 0.04 LOQ
Muscle LOQ 2.27 ± 0.88 3.49 ± 0.73 4.23 ± 1.02 2.32 ± 1.37 0.26 ± 0.19 0.032 ± 0.05 LOQ 0 LOQ
FIGURE 1 | Diagrams of uptake and elimination of oxolinic acid (OA) at different time points post oral administration of medical feed (25 mg/kg). Concentrations of OA
in plasma (A), head kidney (B), liver (C), and muscle (D). Time points are significant different statistically if they do not shear letter. Measurements above 160 h were
lower than LOQ and not included in the Figure for better visualization.
for FLU were found to be 2.77µg/ml, 7.7 h, 2.5 h, 22 h, 104.3,
and 50.3 h µg/ml, respectively. The calculated pharmacokinetic
values for OA and FLU in plasma, muscle, head kidney and liver
are given in Tables 3, 4, respectively.
Susceptibility (MIC) to OA and FLU was tested in 28 isolates,
typical and atypical, of A. salmonicida isolated from diseased
lumpfish. The distribution of MIC‘s for the atypical isolates (n
= 22) was from 0.024 to 0.2µg/ml with a median wild type (WT)
MIC of 0.098 for FLU and 0.23µg/ml for OA (0.059–0.47µg/ml).
One atypical isolate displayed a MIC value of 3.78µg/ml for OA
and 0.78µg/ml for FLU. The typical A. salmonicida isolates (n=
5) had a distribution of MIC‘s from 3.75 to 15µg/ml for OA and
0.78 to 6.25µg/ml for FLU.
DISCUSSIONS
Studies have revealed major variances in the pharmacokinetic
properties of OA and FLU in different fish species, supporting the
argument that such studies should be performed in the species
for which a particular compound is intended used. In the current
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FIGURE 2 | Diagrams of uptake and elimination of flumequine (FLU) at different time points post oral administration of medical feed (25 mg/kg). Concentrations of FLU
in plasma (A), head kidney (B), liver (C), and muscle (D). Time points are significant different statistically if they do not shear letter. *Measurement in one of six fish at
120 h was an outlier and not included in the diagram.
TABLE 3 | Calculated pharmacokinetic parameters for oxolinic acid in plasma,
muscle, head kidney, and liver of lumpfish following a single oral administration of
25 mg/kg.
Tissue AUC AUC0−24 Cmax Tmax (h) T1/2β (h)
Plasma 61 h µg/ml 34 h µg/ml 2.1µg/ml 10.3 21
Muscle 137 h µg/g 4.0µg/g 11.1 15
Liver 102 h µg/g 3.0µg/g 9.2 22
Head kidney 139 h µg/g 4.7µg/g 10.0 19
AUC, Area Under Curve; AUC0−24, Area Under Curve from 0 to 24 h; Cmax , maximum
concentration; Tmax , time to maximum concentration; t1/2β, elimination half-life.
study, we have used LC-MS/MS, which is an rapid method to
determine the concentration of drug residues (29). In previous
study, we used this method for determination of uptake and
elimination of florfenicol in lumpfish (26).
Following a single oral administration of OA or FLU to
lumpfish, a one-compartment open model with first-order
input and first-order output best described the mean plasma
concentrations vs. time curve for both compounds. This model
was previously used to describe single oral administration of OA
in Atlantic salmon, Atlantic halibut, and Atlantic cod (19, 21,
22, 24) and FLU in Atlantic salmon (19). In Atlantic halibut,
however, single oral administration of FLU was best described by
a two-compartment model (20).
Tmax is a suitable indicator to describe the absorption rate
following an oral administration of a drug. In lumpfish, the
TABLE 4 | Calculated pharmacokinetic parameters for flumequine in plasma,
muscle, head kidney (H-kidney), and liver of lumpfish following a single oral
administration of 25 mg/kg.
Tissue AUC (h µg/ml) AUC0−24 (h µg/ml) Cmax Tmax (h) T1/2β (h)
Plasma 104 h µg/ml 50 h µg/ml 2.8µg/ml 7.7 22
Muscle 144 h µg/g 4.2µg/g 10.2 15
Liver 198 h µg/g 4.0µg/g 10.3 22
Head kidney 217 h µg/g 7.5µg/g 6.0 24
AUC, Area Under Curve; AUC0−24, Area Under Curve from 0 to 24 h; Cmax , maximum
concentration; Tmax , time to maximum concentration; t1/2β, elimination half-life. Data for
head-kidney did not fit any model and Cmax and Tmax values are therefore from Table 2.
plasma Tmax for OA was calculated to 10.3 h indicating faster
absorption than in Atlantic halibut, Atlantic cod, Atlantic
salmon, rainbow trout (Oncorhynchus mykiss Walbaum, 1792)
and sharpsnout sea bream (Diplodus puntazzo Walbaum, 1792)
where plasma Tmax values ranged from 19 to 24 h (21, 22, 24, 30–
32). While the absorption rate for FLU was fast in lumpfish
(plasma Tmax of 7.7 h) considerable variation in plasma Tmax has
been documented in other fish species, with 6, 10, and 13.7 h
in Atlantic salmon, 7 h in turbot (Scophthalmus maximus L.), 7
and 20 h in Atlantic halibut and 24 h in Atlantic cod (19, 20,
25, 33, 34). In a recent study, a Tmax of 21.2 h was found for
FFC in lumpfish held at 12◦C (26), hence a significantly slower
absorption rate compared to FLU and OA.
The maximum plasma concentration (Cmax) of 2.12µg/ml
for OA in lumpfish was higher than in Atlantic cod and
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Atlantic halibut (1.2µg/ml) (21), and Atlantic salmon (0.61
and 0.87µg/ml), using the same dose (19, 24, 31). A single
administration of 30 mg/kg gave Cmax of 0.92 in sharpsnout
sea bream (32). The plasma Cmax for FLU was calculated to
2.77µg/ml in lumpfish and is thus comparable to Atlantic
halibut (2.7µg/ml) and Atlantic salmon (2.6µg/ml) (21, 34). In
comparison, a single administration of 10 mg/kg gave Cmax of
3.5µg/ml in Atlantic cod and 1.9µg/ml in turbot (24, 25).
Since single intravenous injection of the drugs was not
included in this study, the distribution volume (Vd) could not
be determined. However, an alternative method to describe
the distribution of a compound from blood to tissues is to
use the AUC values in Tables 3, 4 to estimate tissue/plasma
ratios. For OA these ratios were 2.3, 1.6, and 2.3 for muscle,
liver, and head kidney, respectively, in lumpfish. Corresponding
ratios for FLU were 1.3, 1.9, and 2.1 respectively and
indicate a satisfactory tissue distribution for both compounds.
In muscle and liver of Atlantic salmon, the tissue/plasma
ratios for OA where calculated to 5.7 and 5.9, respectively,
demonstrating a much better distribution of OA in this species
compared to lumpfish (22). In a similar pharmacokinetic
study of FFC in lumpfish, only the head kidney/plasma
ratio exceeded 1.0, indicating a substantial lower distribution
of florfenicol (26).
Plasma elimination half-lives (t1/2β) of OA and FLU in fish are
temperature and species dependent. An elimination half-life of
21 h in lumpfish is comparable to reported t1/2β values of 18.2 h
(10.2◦C) and 18 h (10◦C) for OA in Atlantic salmon, and shorter
than in Atlantic cod and halibut which demonstrated plasma
t1/2β values of 82 and 48 h (8
◦C), respectively (19, 21, 22, 24).
Sea bream eliminate OA at a high rate with calculated half-
lives of 10 and 12.6 h at 19oC (28). A similar tendency was
seen for FLU with t1/2β values of 22 h in lumpfish and 22.4
and 22.8 h in Atlantic salmon (19, 35) compared to 74 h in
Atlantic cod and 43 h in Atlantic halibut at temperatures of
8 and 10◦C, respectively (20, 33). The half-lives of OA and
FLU in lumpfish range from 15 h in muscle to 22 h in liver
for OA and from 15 in muscle to 24 h in head kidney for
FLU. Hence, minor difference in elimination half-lives between
the organs.
To maximize treatment efficacy and minimize the risk of
development of bacterial resistance, pharmacokinetic knowledge
combined with susceptibility tests (MIC), are important tools for
establishment of optimal antibacterial dosage regimes. A peak
concentration Cmax/MIC ratio of at least 8 has been suggested to
obtainmaximum efficacy and prevent resistance development for
bactericidal drugs that act mainly by concentration-dependant
mechanisms such as FLU and other fluoroquinolones (36).
Although OA is listed as a bacteriostatic drug (Summary of
Product Characteristics (SPC), www.felleskatalogen.no/medisin-
vet.), Barnes et al. (37) suggested that the activity of OA against
A. salmonicida was concentration dependent and Wright et al.
(38) recommended that the mode of action of the quinolones is
best considered as concentration dependent. We have therefore
evaluated the efficacy of both OA and FLU using Cmax/MIC ratio
as the PK/PD indices. The relevant pharmacokinetic parameter
for OA and FLU is plasma Cmax which is 2.12 and 2.77µg/ml
for these substances, respectively. In the literature describing
the pharmacokinetics of OA and FLU in fish, the plasma
concentrations of the drugs are given as total concentration,
including free and bound to plasma protein. If the total drug
concentration was used in setting Cmax/MIC ≥ 8 for the
PK/PD indices, then the critical breakpoint MIC values (Cmax/8)
could be estimated to 0.265 and 0.346µg/ml for OA and FLU,
respectively. This indicates clinical efficacy for most of the
atypical strains using OA and all atypical strains using FLU
while all typical strains tested can be classified as resistant for
both drugs, indicating low or no clinical efficacy. If, on the
other hand, free drug was used in setting ≥8 for Cmax/MIC, the
Cmax value must be adjusted accordingly. The plasma protein
binding of OA and FLU in lumpfish is, as for many fish species,
unknown. Bjørklund and Bylund (39) reported a 27% plasma
protein binding of oxolinic acid in rainbow trout and Plakas
et al. (40) found variable but saturable plasma protein binding
(88–55% at 0.125–8.0µg/ml) of FLU in channel catfish (Ictalurus
punctatus Rafinesque, 1818). Assuming a plasma protein binding
of 27 and 55%, respectively for OA and FLU in lumpfish,
the Cmax values of free drugs can be calculated to 1.54µg/ml
for OA and 1.25µg/ml for FLU and thereby altering critical
breakpoint MIC values to 0.193µg/ml for OA and 0.156µg/ml
for FLU.
CONCLUSION
The availability of pharmacokinetic data and MIC determination
provide an important theoretical basis for calculation of efficient
antibacterial treatment and for calculation of suitable withdrawal
periods. Our results indicate that an oral administration of
25 mg/kg of OA or 25 mg/kg FLU will only be sufficient
in treating lumpfish infected with sensitive A. salmonicida
isolates. For the strains that are less sensitive to quinolones,
an increase in dose will be required to improve efficacy.
Otherwise, alternatives like florfenicol should be considered.
Sensitivity testing prior to treatment of diseased lumpfish is
crucial and recommended doses should be tested experimentally.
Effective treatment is important for reducing the risk of
development of antimicrobial resistant bacteria and for the
welfare of lumpfish.
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